Baidu
map

心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Heart：TAVI后患者早期死亡的预测因素

2014-04-22 小田 译 医学论坛网

TAVI早期死亡预测因素
关注

法国学者探讨了经导管主动脉瓣置入术(TAVI)后患者早期死亡的预测因素并试图制作并验证一种较为简便的危险评分方法。结果表明，TAVI术后患者早期死亡主要与年龄、症状严重度、并存疾病和经心尖途径操作有关。一种简单的评分可用于预测患者TAVI后早期死亡，但对于高危患者的精确鉴别而言，这种评分方法的中度鉴别力为其局限性。研究论文4月16日在线发表于《心脏》(Heart)杂志。 该研究将3833例序贯性

法国学者探讨了经导管主动脉瓣置入术(TAVI)后患者早期死亡的预测因素并试图制作并验证一种较为简便的危险评分方法。结果表明，TAVI术后患者早期死亡主要与年龄、症状严重度、并存疾病和经心尖途径操作有关。一种简单的评分可用于预测患者TAVI后早期死亡，但对于高危患者的精确鉴别而言，这种评分方法的中度鉴别力为其局限性。研究论文4月16日在线发表于《心脏》(Heart)杂志。

该研究将3833例序贯性患者随机分为两个队列，每个队列分别有2552例和1281例患者，分别制定和验证一种预测30天或院内死亡的评分系统。

结果显示，应用爱德华Sapien假体和美敦力Corevalve瓣膜的患者数分别为2551例 (66.8%)和1270 例(33.2%)。经股动脉途径、经心尖途径、经锁骨下途径和其他途径操作的患者数分别为2801 (73.4%)、678 (17.8%)、219 (5.7%)和117 (3.1%)。共382例(10.0% )患者发生早期死亡。多变量回归模型分析显示，早期死亡的预测因素为年龄≥90岁、体质指数(BMI)<30 Kg/m2、纽约心功能分级(NYHA)IV级、肺动脉高压、危险的血流动力学状态、过去一年中≥2次的肺水肿、呼吸衰竭、透析和经心尖途径或其他途径(经主动脉途径和经颈动脉途径)操作。研究者推导出了21预测评分法(21-point predictive score)，在制定和验证队列中，这种评分法与观察到的30天死亡率有较好的一致性。

原始出处：


Iung B1, Laouénan C, Himbert D, Eltchaninoff H, Chevreul K, Donzeau-Gouge P, Fajadet J, Leprince P, Leguerrier A, Lièvre M, Prat A, Teiger E, Laskar M, Vahanian A, Gilard M; for the FRANCE 2 Investigators.Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score.Heart. 2014 Apr 16. doi: 10.1136/heartjnl-2013-305314. 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1973239, encodeId=f82619e3239d1, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Mon Jan 26 17:17:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264203, encodeId=09151264203df, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355853, encodeId=dd461355853c9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562230, encodeId=3ee11562230dd, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=)]
    2015-01-26 yuhaisheng_ibp_32061711

    #早期死亡#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1973239, encodeId=f82619e3239d1, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Mon Jan 26 17:17:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264203, encodeId=09151264203df, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355853, encodeId=dd461355853c9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562230, encodeId=3ee11562230dd, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=)]
    2014-04-24 朱睿睿

    #预测因素#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1973239, encodeId=f82619e3239d1, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Mon Jan 26 17:17:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264203, encodeId=09151264203df, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355853, encodeId=dd461355853c9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562230, encodeId=3ee11562230dd, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=)]
    2014-04-24 zhaojie88

    #ART#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1973239, encodeId=f82619e3239d1, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Mon Jan 26 17:17:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264203, encodeId=09151264203df, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355853, encodeId=dd461355853c9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562230, encodeId=3ee11562230dd, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=)]
    2014-04-24 爆笑小医

    #HEART#

    0

相关资讯

JACC：警惕TAVI后冠脉闭塞

加拿大一项研究表明，经导管主动脉瓣置入（TAVI）后症状性冠脉闭塞为罕见的致命性并发症，好发于女性，近期和远期死亡率均较高。论文8月在线发表于《美国心脏病学会杂志》（J Am Coll Cardiol）。【原文下载】 此项研究共纳入44例TAVI后出现症状性冠脉闭塞的患者，并对基线和操作特征、治疗以及临床转归进行了评估。22例冠脉闭塞患者和345例对照患者具有TAV

AHA2012年会：TAVI同行起搏器置入不改善生存率

　　法国一项研究发现，对经皮主动脉瓣置换术（TAVI）患者同时或术后置入起搏器对中期生存预后无效，反而增加住院时间。该研究在美国心脏学会（AHA）2012科学年会上报告。 　　研究将TAVI患者分成起搏器置入组和非起搏器置入组，比较了30天和1年的随访结果。所有病人均在6年研究期间（2006-2012）在法国的3所三级医疗中心的任意一所接受治疗。共有960例接受了TAVI，其中70%为爱德华公司

JACC：经导管主动脉瓣置入（TAVI）可用于主动脉瓣反流

　　英国学者的一项研究表明，利用经导管主动脉瓣置入（TAVI）治疗天然主动脉瓣反流（NAVR）可行但具有一定难度。论文于2013年2月14日在线发表于《美国心脏病学会杂志》（J Am Coll Cardiol）。 　　此项回顾性研究从14个中心共纳入43例接受TAVI的患者。受试者平均年龄75.3 ± 8.8岁，女性为53%，平均Logistic

介入心脏病学领域聚焦非冠脉领域

　CIT的十年，见证了中国介入心脏病学领域的蓬勃发展，冠心病介入治疗如火如荼开展的同时，介入治疗也在逐步走进非冠脉领域。心律失常射频消融风头正劲，我国数万例先天性心脏病患者接受了介入治疗，经皮导管去肾交感神经术（RSD）治疗顽固性高血压也已露出“尖尖角”……有人预言，介入心脏病学的下一个高潮将出现在非冠脉领域。 　　顽固性高血压：RSD起步阶段，注重实践与交流 　　本届CIT在开幕式前安排了

王建安：经导管主动脉瓣置入术（TAVI）的手术适应证及技术要点

到目前为止，全球实际上已实施了8万多例经导管主动脉瓣置入术，这项技术已经非常成熟。欧美国家的心血管学界认为，TAVI是介入心脏病学一个新的突破，它很可能会取代原来的外科手术，大大减低由手术引发的出血、感染、脑中风等并发症的风险。 一、PARTNER研究解读     PARTNER研究是一项大型、多中心、随机对照研究。研究分为两个队列，A队列入选了外科手术高危的、重度钙

葛均波：TAVI基本要素——现场准备、心脏团队及患者选择

葛均波复旦大学附属中山医院  院士    TAVI是近十年来介入心脏病学领域一项令人鼓舞的技术。TCT主席Leon曾说：“以TAVI为代表的结构性心脏病介入治疗将成为今后心 血管介入治疗创新发展的最重要方向。”那么确保TAVI的顺利进行，它需要具备哪些基本要素呢？根据我们团队的经验，我们将从现场准备、心脏团队以

Baidu
map
Baidu
map
Baidu
map